Innovative Vector Control Consortium (IVCC)
Vector-borne neglected tropical diseases (NTDs) and malaria are major causes of mortality, morbidity and lack of economic progress for the poorest. Targeting the vector (mosquito) is a main eradication approach. Due to climate change and natural mutation, insecticide resistance is affecting most malaria endemic countries. The Innovative Vector Control Consortium (IVCC) is the world-leader Product Development Partnership developing innovative and safe insecticides. SDC strategic support to IVCC complements Switzerland’s global action against malaria.
Landwirtschaft und Ernährungssicherheit
Pflanzenschutz & Schädlingsbekämpfung
- Other Academic Research North
Malaria is responsible for over 400,000 death per year mainly in sub-Saharan Africa. Despite great progress over the past 15 years, malaria remains a major global public health issue, with an estimated 3.3 billion people in 97 countries still being at risk of the disease and 214 million cases occurring every year. Control, elimination and eradication of malaria and insect vector-borne NTDs rely heavily on insecticides, particularly in hyper-endemic areas. New vector control tools (mainly insecticides for bed nets and indoor spraying) are needed to address and prevent insecticide resistance. Since 2016, IVCC developed products have protected 119.5 million people.
There are two main avenues to fight vector-borne diseases such as malaria: target the mosquito (vector control) or the parasite itself (case management that includes preventive and curative medicines). Switzerland is playing a leading role in the global fight against malaria: Swiss research institutions, pharmaceutical companies, international NGOs and the official international cooperation are at the forefront on the malaria fight. SDC is active on these both approaches with specific interventions in research and development, funding and policy influencing at the global and bilateral level (i.e. Tanzania).
On the vector control side, IVCC is the world leader public-private partnership in R&D of insecticides being used for Internal Residual Spraying (IRS) and Insecticide mosquito nets. IVCC collaborates closely with the Swiss-based big pharma Syngenta, member of the Swiss Malaria Group. SDC supports four Products Development Partnerships (PDPs) like IVCC. PDPs serve as a platform for R&D of medical products that would otherwise not be developed due to a market failure. IVCC has developed innovative tools such as the Vector Expedited Review Voucher (VERV) that offers expedite approbation process for new insecticides products presented to official agencies. IVCC supports directly seven African research centres and conduct local trials. Developing new insecticides needs long-term commitment. SDC renewed support to IVCC allows sound continuity on R&D and access to new vector controls tools.
|Ziele||To reduce transmission of insect-borne pathogens, and ultimately to improve health and reduce poverty resulting from the burden of these infectious diseases, through improved insect vector control with new and effective products.|
|Zielgruppen||Affected population in vector-borne endemic countries. NTDs and malaria disproportionally falls on the poorest quartile of the population in disease-endemic countries.|
|Mittelfristige Wirkungen||Improved malaria control initiatives using enhanced vector control tools that tackle the threat posed by insecticide resistance.|
1. New vector control products to overcome
2. Addressing technical, policy, regulatory and
3. Maximising product effectiveness through appropriate
Resultate von früheren Phasen:
- Between 2016 and 2019, 9.2 million malaria cases averted
- IVCC has delivered and allowed market uptake of key insecticides:
- Strong partnerships built with pharma companies to keep
Ausländische Hochschul- und Forschungsinstitution
pharmaceutical companies (BASF, Bayer, Mitsui, Syngenta, Sumitomo); research institutions and academics (Swiss TPH).
|Koordination mit anderen Projekten und Akteuren||Organization, Global Fund, PDPs (MMV DNDi), Swiss Malaria Group|
|Budget||Laufende Phase Schweizer Beitrag CHF 4’400’000 Bereits ausgegebenes Schweizer Budget CHF 1’595’000|
|Projektphasen||Phase 3 01.08.2020 - 31.07.2024 (Laufende Phase) Phase 2 01.08.2018 - 31.07.2020 (Completed) Phase 1 01.01.2014 - 31.12.2017 (Completed)|